Futuretech Ii Acquisition CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
FutureTech II Acquisition Corp. reports significant net losses and liquidity challenges, while progressing with its proposed business combination with Longevity Biomedical, Inc. despite a Nasdaq delisting and ongoing operational hurdles.
OTC.Pink
10-Q: FutureTech II Acquisition Corp. Faces Delisting Amidst Proposed Merger with Longevity Biomedical
FutureTech II Acquisition Corp.'s Q1 2025 report reveals a net loss, ongoing efforts to complete a business combination with Longevity Biomedical, and challenges with Nasdaq listing compliance.
OTC.Pink
FutureTech II Acquisition Corp. reports a net loss for Q3 2024 and is working to complete a business combination with Longevity Biomedical, Inc. while addressing Nasdaq compliance issues.
OTC.Pink
FutureTech II Acquisition Corp. has filed an amended quarterly report to correct accounting errors related to due from sponsor, common stock redemption, and notes payable.
OTC.Pink
FutureTech II Acquisition Corp. files an amended quarterly report to correct accounting errors related to sponsor dues, common stock redemption, and notes payable.
OTC.Pink
FutureTech II Acquisition Corp. has restated its Q3 2023 financials due to material accounting errors, impacting redemption calculations and other financial metrics.
OTC.Pink
FutureTech II Acquisition Corp. reports its financial results for the second quarter of 2024, highlighting a net income of $85,119 and ongoing efforts to secure a business combination while facing potential delisting from Nasdaq.
OTC.Pink
FutureTech II Acquisition Corp. reported a net income of $129,577 for the first quarter of 2024, while facing a May 18, 2024 deadline to complete a business combination.